Hannah Slater

These study findings indicated that primary hemostasis and bleeding are dynamic and more interdependent than platelet counts and bleeding in extremely preterm neonates with thrombocytopenia.

The FDA approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors.

This study found that cancer screening decisions among older adults with limited life expectancy were not always informed or intentional and were subject to multiple complex factors.

The FDA extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia to include pediatric patients who are 1 month and older.

The FDA has cleared an investigational new drug application for BPX-603, a GoCAR-T product candidate targeting solid tumors that express human epidermal growth factor receptor 2.

The FDA approved lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer under accelerated approval based on overall response rate and duration of response in a phase 2 study.

Both the phase 2 ACE-CL-001 trial and the pivotal phase 3 ASCEND trial showed the long-term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia.

The FDA approved an expanded indication for the HPV 9-valent vaccine, recombinant for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.

Researchers indicated that these results support the use of telemedicine as an improved model for patient care during adjuvant chemotherapy.

In this retrospective cohort study, the use of immune checkpoint inhibitors among patients with advanced NSCLC with negative, low, or untested PD-L1 expression was found to have increased over time.

Rencsok and colleagues found that the proportion of white participants in the clinical trials studied has primarily remained above 80% since 1990.

Pegfilgrastim-apgf is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Due to population changes alone, researchers indicated national cancer-attributed medical care costs in the US are considerable and predicted to increase dramatically by the year 2030.

The American Cancer Society published new guidelines focused on staying at a healthy weight, staying active throughout life, adhering to a healthy eating pattern, and avoiding or limiting alcohol.

The trial is evaluating pembrolizumab in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma.

A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia/lymphoblastic lymphoma who are hypersensitive to E. coli-derived asparaginases was announced at the 2020 ASCO Virtual Scientific Program.

Trends in favor of better clinical outcomes were observed for those on-trial in this retrospective matched cohort study of patients with cancer who were treated on a phase III clinical trial compared with those who received standard therapy and/or were off trial.

A recent study demonstrated the validity of current breast cancer testing panels for use in African American women and provides a basis for increased referral of this patient population for cancer genetic testing.

It was suggested that telemedicine for patients in an interventional radiology group increases access to care and allows for more efficient use of physician time and resources.

It was suggested that telemedicine for patients in an interventional radiology group increases access to care and allows for more efficient use of physician time and resources.

In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the use of endoscopy for acute upper gastrointestinal bleeding.

Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

The FDA approved ramucirumab injection in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 mutations.

The results suggested the potential for this agent to become a new standard for T-suppression in this patient population.

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

The results, presented at the 2020 ASCO Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer who were previously treated with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel.

Front-line therapy with pembrolizumab doubled progression-free survival versus chemotherapy in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.

Researchers detailed methods and processes that may be useful for additional research and validation of computational hematoxylin and eosin staining deep learning models and the images generated by them.

The research scientist spoke about the study that found that fine particulate matter pollution was associated with mortality in pediatric, adolescent, and young adult patients with specific cancers.

Payment models with shared-savings components, such as the Oncology Care Model, may be associated with fewer visits and lower costs in certain cancer settings in the first year.